How many generations of targeted drugs are capisete tablets/caposetinib divided into?

Capivasertib (Capivasertib) is classified as a new generation pan-AKT inhibitor. It is a kinase inhibitor targeted drug in tumor treatment and has clear molecular targets and mechanisms. It does not belong to the traditional "first generation" and "second generation" classification methods, but is classified based on "target type" and "action mechanism". Caposetinibis a highly selectiveATP competitive inhibitor that can simultaneously inhibit the three main subtypes in the AKT pathway: AKT1, AKT2 and AKT3. By binding to the ATP binding site of AKT, capositinib can effectively block the downstream signal activation of the PI3K/AKT/PTEN signaling pathway, thereby interfering with cell proliferation, survival and tumor progression.

The molecular design of this drug represents the forefront of the development of AKT-targeted drugs, especially in solving the problem of resistance to previous single-point inhibitors of PI3K or AKT. Due to its "pan-AKT inhibition" feature, capositinib can cover multiple AKT mutation subtypes, improving the breadth and depth of treatment. More importantly, compared with the first-generation AKT inhibitors, it has significantly improved selectivity, tissue penetration and tolerability, reducing the incidence of common side effects such as hyperglycemia and rash. Therefore, it is considered one of the representative drugs of the "new generation of precise AKT pathway targeting drugs".

In terms of the classification of targeted therapy drugs, capositinibbelongs to the kinase targeted inhibitors, which is similar to EGFR, ALK, HER2 and other tyrosine kinase inhibitors, but its uniqueness lies in directly targeting AKT, the core signaling axis of tumor metabolism and survival. This mechanism also determines its broad applicability in tumors related to abnormalities in the PIK3CA/AKT/PTEN pathway, such as breast cancer, prostate cancer, and ovarian cancer. Compared with traditional chemotherapy, capositinib belongs to the field of precision medicine, which emphasizes target matching and personalized medication. Its side effect management, efficacy evaluation and treatment schedule all need to be combined with molecular testing results.

Reference materials:https://www.drugs.com/mtm/capivasertib.html